Novartis, Teva End Long-Running Lotrel Patent Suit

Law360, New York (July 21, 2011, 4:14 PM EDT) -- Novartis Corp. and Teva Pharmaceuticals USA Inc. buried the hatchet Wednesday in a seven-year-old patent dispute in New Jersey over hypertension drug Lotrel, with a federal judge approving a settlement.

U.S. District Judge Garrett E. Brown Jr. signed off on the agreement, which resolves the case over Teva's generic version of Novartis' Lotrel. The parties settled two separate cases, each of which involve the same patent but different dosage strengths.

"Under the agreement, Teva admits to the validity of the Novartis patents and that they have...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.